Mitochondria may be best known for fueling cells, but new research reveals they also play a surprising role in the spread of cancer.
Rockefeller researchers have discovered that the antioxidant
glutathione, acting within mitochondria, plays a crucial role in allowing
breast tumors to spread to the lung.
Mitochondria are best known as the
cell’s powerhouse, but growing evidence indicates they also play a central role
in driving cancer. New research has identified the mitochondrial metabolite
glutathione as a key factor that enables breast cancer cells to detach from the
primary tumor, spread through the body, and establish themselves in new
tissues.
The findings are among the first to
link a specific mitochondrial metabolite to metastasis, with strong
implications for the study of cancer at the cellular level. “We hope that our
work will bring more attention to how organelles and their metabolites are
relevant to cancer biology,” says Kivanç Birsoy, head of the Laboratory of
Metabolic Regulation and Genetics at Rockefeller.
A mysterious connection with metastasis
Most cancer deaths occur not because
of the original tumor, but due to the disease’s spread. Because metastasis is
the leading cause of cancer mortality, researchers have long sought to uncover
the mechanisms that allow cancer cells to break free from their primary site
and colonize distant organs.
Yet the exact molecular players
remained unclear. “Mitochondria have thousands of metabolites, and it’s been
difficult to determine which are important to tumor formation and growth, and
which initiate metastasis,” Birsoy explains.
Cells under stress
To address this question, Birsoy and
his colleagues used a protein-tagging approach that allowed them to distinguish
between cells that remained in the breast tumor and those that had spread to
the lung. Led by graduate fellow Nicole DelGaudio and postdoctoral fellow
Hsi-wen Yeh, the team then examined how the metabolite composition of
mitochondria changed when cancer cells established themselves in new tissues.
“These techniques allowed us to, in
an unbiased manner, see the difference between what’s essential in metastasis
and what’s essential in the primary tumor,” DelGaudio says.
Out of thousands of mitochondrial
metabolites, glutathione emerged as a striking candidate. This antioxidant,
known for reducing oxidative stress, aiding detoxification, and supporting
immune function, was found in sharply elevated levels within metastatic cancer
cells that had reached the lung. To validate the observation, the researchers
employed spatial metabolomics to directly visualize glutathione distribution in
lung tissues.
The investigation then shifted toward
mitochondrial membrane proteins. Screening revealed that one stood out as
indispensable for metastatic cancer cells: SLC25A39, the transporter that
imports glutathione into mitochondria. Together, the findings established a
direct connection between glutathione and its transporter, showing that
mitochondrial glutathione import through SLC25A39 is a critical driver of cancer
metastasis.
Birsoy
and colleagues also found how mitochondrial glutathione drives cancer spread:
not by acting as an antioxidant—an effect ruled out through multiple
experiments—but by signaling to activate ATF4, a transcription factor that
helps cancer cells survive in low-oxygen conditions. This also pinpointed when
glutathione is specifically required: during the early steps of metastatic
colonization, when cancer cells adapt rapidly to the stressful environment of a
new tissue.
A familiar culprit
This work builds on recent significant work from
the Birsoy lab. In 2021, his team was the first to demonstrate that SLC25A39 is
the transporter that brings glutathione into the mitochondria; in 2023, they
showed that SLC25A39 is not only a transporter but a dynamic sensor that
regulates the amount of glutathione in the mitochondria and adjusts those
levels accordingly. So when this metabolite and its mitochondrial transporter
showed up in cancer screenings, Birsoy knew where to take his experiments next.
“Because we found this transporter
earlier and knew how to block the entry of glutathione, we already had the
tools necessary to investigate its role in cancer metastasis,” he says.
The findings may have clinical
implications—especially since the team also found that breast cancer samples
from patients whose disease had spread to the lung showed elevated SLC25A39,
and that higher SLC25A39 expression was strongly correlated with poorer overall
survival in breast cancer patients. One day, a small molecule that targets this
metabolite by blocking its transporter could potentially forestall breast
cancer metastasis, with fewer side effects than sweeping therapies that target
more general cellular processes.
In the short term, however, the paper
emphasizes the importance of nailing down just how metabolites within different
compartments operate within our cells.
“We’re trying to make our knowledge of metabolism more precise,” Birsoy says. “It’s not just about some metabolite levels going up and others going down. We need to look at the organelles, the precise compartments, to understand how metabolites influence human health.”
No comments:
Post a Comment